Back To: Home : Featured Technology : High Throughput Screening

CLICK HERE FOR WHAT'S NEW IN:
 

Promega, Puracyp merge cell lines, assay systems
October 2011
SHARING OPTIONS:

MADISON, Wis.Puracyp Inc. and Promega Corp. recently came together to provide all-inclusive kits for the assessment of nuclear receptor activation, P450 metabolism and cellular toxicity during the development process. The kits boast components that are designed and tested to work together in comprehensive user protocols. Puracyp brings to the table its proprietary nuclear receptor expressing cell lines, while Promega brings its assay and detection technologies for bioluminescent reporters, cell viability and P450-Glo substrate-based metabolism assays. In addition, the two companies have also launched a product line made up of DPX2 cells (human PXR), rPXR cells (rodent PXR), MkB3 cells (monkey PXR) and 1A2-DRE cells (human AhR). The cell-based assay systems are compatible to multiplexing in which activation, metabolism and toxicity can be assessed in one well of a 96- or 384-well plate.

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.